Navigation Links
Angiotech Pharmaceuticals, Inc. announces financial results for the second quarter ended June 30, 2009
Date:8/6/2009

ts or developments to be materially different from any future results, events or developments expressed or implied by such forward-looking statements. Many such known risks, uncertainties and other factors are taken into account as part of our assumptions underlying these forward-looking statements and include, among others, the following: general economic and business conditions in the United States, Canada and the other regions in which we operate; market demand; technological changes that could impact our existing products or our ability to develop and commercialize future products; competition; existing governmental regulations and changes in, or the failure to comply with, governmental regulations; availability of financial reimbursement coverage from governmental and third-party payers for products and related treatments; adverse results or unexpected delays in pre-clinical and clinical product development processes; adverse findings related to the safety and/or efficacy of our products or products sold by our partners; decisions, and the timing of decisions, made by health regulatory agencies regarding approval of our technology and products; the requirement for substantial funding to conduct research and development, to expand manufacturing and commercialization activities; and any other factors that may affect our performance. In addition, our business is subject to certain operating risks that may cause any results expressed or implied by the forward-looking statements in this Quarterly Report on Form 10-Q to differ materially from our actual results. These operating risks include: our ability to attract and retain qualified personnel; our ability to successfully complete pre-clinical and clinical development of our products; changes in our business strategy or development plans; our failure to obtain patent protection for discoveries; loss of patent protection resulting from third-party challenges to our patents; commercialization limitations imposed by p
'/>"/>
SOURCE Angiotech Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28

Related biology technology :

1. Angiotech announces additional diameters of sutures to further expand its Quill(TM) SRS PDO product line
2. Angiotech receives favourable patent decision from New Zealands Intellectual Property Office
3. Angiotech reaches agreement with Johnson & Johnson to settle outstanding patent litigation
4. Angiotech to participate in UBS Global Life Sciences Conference
5. Angiotech announces intent to file 510(k) for its innovative 5-FU Central Venous Catheter (CVC) based on positive results from pivotal trial
6. Angiotech Receives CE Mark Approval of Quill(TM) SRS MONODERM(TM), a New Rapidly Resorbing Suture Product Line
7. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
8. Angiotech to participate in Bank of America 2007 Credit Conference
9. Angiotech to participate in RBC 2007 Healthcare Conference
10. Angiotech Submits 510(K) To FDA For Its Innovative 5-FU CVC
11. Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/2/2015)... , March 2, 2015  Pfenex Inc. (NYSE ... the development of biosimilar therapeutics, today announced that ... Global Healthcare Conference in Miami, FL at the Loews Miami ... executive officer of Pfenex, will provide an overview ... on March 12th at 9:00 am ET. A live audio webcast ...
(Date:3/2/2015)... Sterlitech is proud to debut its multi-line, ... 2015 AMTA Membrane Technology Conference in Orlando. This ... of engineering and customer feedback, which has resulted in ... applications across an array of disciplines. It is ... needs of researchers and engineers alike and is ideal ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Immunovaccine Inc. ... aware of a fraudulent press release disseminated this morning ... be from Immunovaccine. This press release states that Immunovaccine ... Inc. The press release did not originate from ... contained within the press release. Please note that ...
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
Breaking Biology Technology:Sterlitech Displays Complete CF042 Membrane Test System 2Immunovaccine Disclaims Hoax Press Release 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3
... November 1, 2011 - Listed companies to present ... 30 - December 2 Elsevier Business Intelligence ... to Watch list. The list delivers projects and companies with ... growth through investments in deals. This year,s list includes ...
... Colo., Oct. 31, 2011 Azantis launches today AstaKrill™ ... Azantis , a leading krill oil manufacturer, markets AstaKrill to ... antioxidant that gives krill its distinct red color. The astaxanthin ... in other krill oils currently on the market. ...
... 2011 Reportlinker.com announces that a ... in its catalogue: ... Opportunity Assessment and Market Forecasts to ... Spinal Implants - ...
Cached Biology Technology:Windhover Announces the "Top Biopharma Projects to Watch" 2Windhover Announces the "Top Biopharma Projects to Watch" 3AstaKrill™ the Best Krill Oil Boosts Astaxanthin 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 2Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 3Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 4Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 5Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 6Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 7Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 8Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 9Spinal Implants - Global Pipeline Analysis, Opportunity Assessment and Market Forecasts to 2016 10
(Date:2/24/2015)... , Feb. 24, 2015 Research and ... the addition of the "Global 2D Gesture ... The analysts forecast the Global ... CAGR of 32.12% over the period 2014-2019 ... in non-traditional sectors is one of the major ...
(Date:2/19/2015)... 2015 Research and Markets ( ... "Military Electro-Optical / Infrared Systems Market by ... - Forecast to 2020" report to their ... market is expected to reach $16.35 billion by ... This report segments the military electro-optical/infrared systems ...
(Date:2/13/2015)... TAIPEI , Feb. 13, 2015 ... service company that aims to transform cancer genomic ... announced that the company has raised US$ 8 million ... Based in Taipei, Taiwan ... tests, ACTDrug™, ACTOnco™. With the aim to implement ...
Breaking Biology News(10 mins):Global 2D Gesture Recognition Market 2015-2019 with Cognitec Systems, CogniVue, eyeSight Mobile Technologies & PointGrab Dominating 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 2Military Electro-Optical / Infrared Systems (Image Intensification, Laser, Infrared) Market - Forecast to 2020: Featuring Profiles of the Market Leaders on this $16 Billion market 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... SALT LAKE CITY -- Climate change spells trouble ... mountains, coastal forests and relatively small areas and ... habitat loss, disease and competition among species. That ... 200 scientific studies relevant to the topic. The review ...
... To maintain power, oil-rich governments often lean on their ... damage their companies, efficiency and raise prices for the ... Mark Thurber. The state-owned oil companies, like Saudi ... control 73 percent of the world,s oil reserves, dwarfing ...
... NY, February 15, 2012Therapeutic cancer vaccines, which stimulate ... cancer cells, are being used in combination with ... several illuminating articles in Cancer Biotherapy and ... Liebert, Inc. ( http://www.liebertpub.com ). These articles are ...
Cached Biology News:Climate change threatens tropical birds 2Climate change threatens tropical birds 3Climate change threatens tropical birds 4Climate change threatens tropical birds 5Book examines state-owned oil firms, prices and pollution 2Book examines state-owned oil firms, prices and pollution 3Promising early results with therapeutic cancer vaccines 2
...
... Purity is >95%\nNEN Radiolabeled Ligands\n\nReceptor-related research has ... of new radiolabeled ligands selected to keep ... wide range of products and services for ... 400 state-of-the-art radioligands. If you do not ...
... The Polymerase gene from Thermus ... expressed in E. coli, then highly ... It is used in the amplification ... PCR. The quality of the Taq ...
... iTaq DNA polymerase is an ... for both conventional and real-time ... supplied at a concentration of ... includes 5,000 units polymerase, 25 ...
Biology Products: